Multivariable landmark analysis
| . | HR . | 95% CI . | P . |
|---|---|---|---|
| ST2 | |||
| Age 10 years or younger | 4.82 | 1.89-14.66 | .0056 |
| Age older than 10 years | 1.72 | 0.82-3.58 | .1484 |
| Malignant disease | 1.16 | 0.52-2.61 | .7143 |
| White, non-Hispanic | 0.79 | 0.42-1.51 | .4813 |
| PBSC transplant source | 1.61 | 0.72-3.64 | .2482 |
| GVHD prophylaxis (reference group, MTX and CNI) | |||
| ATG/alemtuzumab/PT-CY | 3.12 | 0.94-10.43 | .0639 |
| MMF and CNI | 2.07 | 0.56-7.66 | .2750 |
| Sirolimus | 2.94 | 0.90-9.63 | .0747 |
| Age category | 1.89 | 0.74-4.81 | .1786 |
| ST2: landmark | 1.00 | 0.99-1.01 | .8436 |
| . | HR . | 95% CI . | P . |
|---|---|---|---|
| ST2 | |||
| Age 10 years or younger | 4.82 | 1.89-14.66 | .0056 |
| Age older than 10 years | 1.72 | 0.82-3.58 | .1484 |
| Malignant disease | 1.16 | 0.52-2.61 | .7143 |
| White, non-Hispanic | 0.79 | 0.42-1.51 | .4813 |
| PBSC transplant source | 1.61 | 0.72-3.64 | .2482 |
| GVHD prophylaxis (reference group, MTX and CNI) | |||
| ATG/alemtuzumab/PT-CY | 3.12 | 0.94-10.43 | .0639 |
| MMF and CNI | 2.07 | 0.56-7.66 | .2750 |
| Sirolimus | 2.94 | 0.90-9.63 | .0747 |
| Age category | 1.89 | 0.74-4.81 | .1786 |
| ST2: landmark | 1.00 | 0.99-1.01 | .8436 |